2010 Fiscal Year Final Research Report
Angiotensin II-induced hypertension enhanced delivery of liposomal anti-cancer drugs into tumor
| Project/Area Number |
20790146
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Hoshi University |
|---|
Principal Investigator |
HATTORI Yoshiyuki Hoshi University, 薬学部, 准教授 (90350222)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Keywords | ドラッグデリバリー / 昇圧化学療法 / リポソーム / アンギオテンシンII / がん治療 |
|---|
| Research Abstract |
In this study, we investigated whether the therapeutic efficacy of liposomal doxorubicin (DXR-SL) could be enhanced by angiotensin II (AT)-induced hypertension. AT-induced hypertension increased the volume of tumor blood flow in mice bearing a poorly vascularized Lewis lung carcinoma (LLC) tumor, but only slightly in mice bearing a well-vascularized colon carcinoma Colon 26 tumor. In therapeutic efficacy, AT-induced hypertension enhanced the antitumor activity of DXR-SL in mice bearing LLC and Colon 26 tumors. Localization of DXR-SL after injection by AT-induced hypertension was observed outside tumor blood vessels in LLC and Colon 26 tumors, but within them under the normotension. From these findings, AT-induced hypertension had potential to improve the delivery of DXR-SL to both well- and poorly vascularized solid tumors.
|
